1. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
by Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, and Michael Hallek
Blood
Volume 124(14):
October 2, 2014
©2014 by American Society of Hematology

2. Study design and patient disposition in the GAUGUIN study.
Study design and patient disposition in the GAUGUIN study. (A) Phase 1. (B) Phase 2. *One patient enrolled in phase 2 of GAUGUIN did not enter follow-up because of a new anti-leukemia therapy.
Guillaume Cartron et al. Blood 2014;124:
©2014 by American Society of Hematology

3. Complement and cytokine levels over time among phase 1 and 2 study participants.
Complement and cytokine levels over time among phase 1 and 2 study participants. (A) Complement C3 and C4 (mean ± standard deviation). (B) Cytokines (mean ± standard deviation). C, cycle; D, day.
Guillaume Cartron et al. Blood 2014;124:
©2014 by American Society of Hematology

4. Kaplan-Meier plot of PFS in phase 2 of the GAUGUIN study.
Guillaume Cartron et al. Blood 2014;124:
©2014 by American Society of Hematology

5. ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study
ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study. *In phase 1 of GAUGUIN, 4 different doses of obinutuzumab were evaluated.
ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study. *In phase 1 of GAUGUIN, 4 different doses of obinutuzumab were evaluated. In phase 2, all patients received obinutuzumab 1000/1000 mg. The size of the bar below the x-axis reflects the dose received by the patient.
Guillaume Cartron et al. Blood 2014;124:
©2014 by American Society of Hematology

6. Pharmacokinetic and pharmacodynamic properties of obinutuzumab.
Pharmacokinetic and pharmacodynamic properties of obinutuzumab. (A) Mean serum concentrations of obinutuzumab over time. (B) B-lymphocyte count over time in all GAUGUIN study participants. Reported lymphocyte counts are preinfusion for each. FU, follow-up; SD, standard deviation; W, week. The 2 patients who were B-cell depleted at screening were included based on prior CLL diagnoses and lymph node progression.
Guillaume Cartron et al. Blood 2014;124:
©2014 by American Society of Hematology